Harmine (Synonyms: 去氢骆驼蓬碱; Telepathine)

目录号: HY-N0737A 纯度: 99.88%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Harmine 是一种具有抗癌和抗炎活性的天然双特异性酪氨酸磷酸化调节激酶 (DYRK) 抑制剂。Harmine 对 5-HT_2A 血清素受体具有高亲和力，K_i 值为 397 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Harmine Chemical Structure

CAS No. : 442-51-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
100 mg	￥240	In-stock
500 mg	￥500	In-stock
1 g	￥950	In-stock
5 g		询价
10 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Harmine:

MCE 顾客使用本产品发表的 21 篇科研文献

: Harmine purchased from MCE. Usage Cited in: Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79(Pt B):258-267. [Abstract]; Representative images showing the restoration effect of Harmine on CUS-induced decrease in hippocampal DCX protein expressions. The Fluoxetine administration (20 mg/kg) is used as a positive control, and all data are shown as mean±SEM.

Harmine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 DYRK 亚型特异性产品:

查看所有亚型

DYRK1 DYRK2 DYRK3 DYRK4

查看 5-HT Receptor 亚型特异性产品:

查看所有亚型

5-HT₁ Receptor 5-HT₂ Receptor 5-HT₃ Receptor 5-HT₄ Receptor 5-HT₅ Receptor 5-HT₆ Receptor 5-HT₇ Receptor 5-HT Receptor

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT_2A serotonin receptor, with an K_i of 397 nM^[1].

IC₅₀ & Target^[1]^[2]

5-HT_2A Receptor

397 nM (Ki)

DYRK1A

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
769-P	IC₅₀	48.9 μM Compound: 7	Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
A-375	IC₅₀	72.5 μM Compound: 7	Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
A549	IC₅₀	17.12 μM Compound: Harmine	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34425477]
A549	IC₅₀	42.25 μM Compound: Harmine	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
A549	IC₅₀	5.23 μM Compound: HM	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
A549	IC₅₀	5.89 μM Compound: Harmine	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
A549	IC₅₀	52.56 μM Compound: 6; Harmine	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
A549	IC₅₀	7.76 μM Compound: Har	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29129513]
Bel-7402	IC₅₀	54 μM Compound: 1	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 23291116]
Bel-7402	IC₅₀	54 μM Compound: Harmine	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 18462839]
BGC-823	IC₅₀	15.63 μM Compound: HM	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
BGC-823	IC₅₀	63.2 μM Compound: 7	Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
BGC-823	IC₅₀	68 μM Compound: 1	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23291116]
BGC-823	IC₅₀	68 μM Compound: Harmine	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 18462839]
COLO 205	IC₅₀	26 μM Compound: Harmine	Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 22365759]
COLO 205	IC₅₀	46 μM Compound: Harmine	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 22202437]
COLO 205	IC₅₀	8 μM Compound: Harmine	Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
COLO 205	IC₅₀	8 μM Compound: Harmine	Antiproliferative activity against human COLO205 cells by MTT assay Antiproliferative activity against human COLO205 cells by MTT assay	[PMID: 22749421]
DU-145	IC₅₀	12.02 μM Compound: Har	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29129513]
DU-145	IC₅₀	9.63 μM Compound: Harmine	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
HCT-116	IC₅₀	43.8 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HCT-116	IC₅₀	43.8 μM Compound: Harmine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30108831]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29288941]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
HCT-116	IC₅₀	6.94 μM Compound: HM	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HEK293	IC₅₀	0.4 μM Compound: Hrm	Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay	[PMID: 26896709]
HeLa	IC₅₀	> 10 μM Compound: Harmine	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	16.21 μM Compound: Har	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29129513]
HeLa	IC₅₀	60 μM Compound: 1	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23291116]
HeLa	IC₅₀	60 μM Compound: Harmine	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 18462839]
HeLa	IC₅₀	8 μM Compound: Harmine	Cytotoxicity against human HeLa cells after 5 days by MTT assay Cytotoxicity against human HeLa cells after 5 days by MTT assay	[PMID: 30193214]
HeLa	IC₅₀	85.28 μM Compound: 6; Harmine	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HeLa	IC₅₀	9.66 μM Compound: Harmine	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
HepG2	IC₅₀	> 250 μM Compound: HAR	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay	[PMID: 35551033]
HepG2	IC₅₀	> 250 μM Compound: HAR	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay	[PMID: 34274829]
HepG2	IC₅₀	> 250 μM Compound: Harmine	Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay	[PMID: 31812035]
HepG2	IC₅₀	16.8 μM Compound: HM	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HepG2	IC₅₀	46 μM Compound: 1	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 23291116]
HepG2	IC₅₀	46 μM Compound: Harmine	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18462839]
HepG2	IC₅₀	49.96 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 32787089]
HepG2	IC₅₀	51.2 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30108831]
HepG2	IC₅₀	51.2 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29288941]
HepG2	IC₅₀	53.6 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HepG2	IC₅₀	53.6 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31120744]
HGC-27	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HL-60	IC₅₀	62.45 μM Compound: 6; Harmine	Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HL-60	IC₅₀	7.55 μM Compound: 11	Antiproliferative activity against human HL60 cells by tryphan blue assay Antiproliferative activity against human HL60 cells by tryphan blue assay	[PMID: 28128938]
Hs 683	IC₅₀	37 μM Compound: 1	Growth inhibition of human Hs 683 cells after 3 days by MTT assay Growth inhibition of human Hs 683 cells after 3 days by MTT assay	[PMID: 22770529]
Hs 683	IC₅₀	37 μM Compound: 1, Harmine	Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy	[PMID: 25747498]
HT-22	IC₅₀	56.5 μM Compound: 14	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 36876904]
HT-29	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HT-29	IC₅₀	41.8 μM Compound: Harmine	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 32787089]
IMR-32	IC₅₀	38 μM Compound: Harmine	Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay	[PMID: 22365759]
IMR-32	IC₅₀	68 μM Compound: Harmine	Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay	[PMID: 22202437]
K562	IC₅₀	14 μM Compound: Harmine	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
K562	IC₅₀	14 μM Compound: Harmine	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 22749421]
K562	IC₅₀	32 μM Compound: Harmine	Antiproliferative activity against human K562 cells after 24 hrs by MTT assay Antiproliferative activity against human K562 cells after 24 hrs by MTT assay	[PMID: 22365759]
K562	IC₅₀	45 μM Compound: Harmine	Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 22516283]
K562	IC₅₀	45 μM Compound: Harmine	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 22202437]
KB	IC₅₀	57.8 μM Compound: 7	Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
L02	IC₅₀	25.09 μM Compound: HM	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
LoVo	IC₅₀	53.2 μM Compound: Harmine	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	[PMID: 30108831]
LoVo	IC₅₀	53.2 μM Compound: Harmine	Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
MCF7	IC₅₀	10.78 μM Compound: Har	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29129513]
MCF7	IC₅₀	15.27 μM Compound: HM	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
MCF7	IC₅₀	16.94 μM Compound: Harmine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33744443]
MCF7	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	68.33 μM Compound: Harmine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
MCF7	IC₅₀	70.7 μM Compound: 6; Harmine	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
MCF7	IC₅₀	72 μM Compound: Harmine	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18462839]
MDA-MB-231	IC₅₀	21.91 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33744443]
MDA-MB-231	IC₅₀	32 μM Compound: Harmine	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
MDA-MB-231	IC₅₀	32 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 22749421]
MDA-MB-231	IC₅₀	54 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 22516283]
MDA-MB-231	IC₅₀	54 μM Compound: Harmine	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22202437]
MDA-MB-435	IC₅₀	> 100 μM Compound: Harmine	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay	[PMID: 33813152]
MDA-MB-435	IC₅₀	17.1 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay	[PMID: 33813152]
MDCK-II	GI₅₀	2.3 μM Compound: Harmine	Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27280693]
MDCK-II	GI₅₀	2.42 μM Compound: Harmine	Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27280693]
NCI-H2228	IC₅₀	31.06 μM Compound: Harmine	Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34425477]
OE33	IC₅₀	18 μM Compound: 1	Growth inhibition of human OE33 cells after 3 days by MTT assay Growth inhibition of human OE33 cells after 3 days by MTT assay	[PMID: 22770529]
PC-3	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
SGC-7901	IC₅₀	40.82 μM Compound: Harmine	Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
SGC-7901	IC₅₀	70.36 μM Compound: 6; Harmine	Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
SK-OV-3	IC₅₀	74.6 μM Compound: 7	Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
SMMC-7721	IC₅₀	47.6 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
SMMC-7721	IC₅₀	47.6 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 31120744]
SMMC-7721	IC₅₀	55.3 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30108831]
SMMC-7721	IC₅₀	55.3 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29288941]
SMMC-7721	IC₅₀	59.44 μM Compound: Harmine	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
SW-620	IC₅₀	42.8 μM Compound: Harmine	Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
T98G	IC₅₀	24 μM Compound: 1	Growth inhibition of human T98G cells after 3 days by MTT assay Growth inhibition of human T98G cells after 3 days by MTT assay	[PMID: 22770529]
U-373MG ATCC	IC₅₀	32 μM Compound: 1	Growth inhibition of human U373 cells after 3 days by MTT assay Growth inhibition of human U373 cells after 3 days by MTT assay	[PMID: 22770529]
U-87MG ATCC	IC₅₀	7.2 μM Compound: Hrm	Growth inhibition of human U87MG cells after 4 days by MTT assay Growth inhibition of human U87MG cells after 4 days by MTT assay	[PMID: 26896709]

体外研究
(In Vitro)

Harmine 抑制 DYRK1A 催化的 tau 磷酸化 (IC₅₀=190 nM) ；通过干扰 Rad51 招募，负向调控同源重组，导致肝癌细胞严重细胞毒性；联合非同源末端连接 (NHEJ) 抑制剂 Nu7441 显著增强其抗增殖作用^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

结果显示，TBI组脑组织含水量明显增加。与TBI组相比，使用Harmine治疗后1、3和5天的组织含水量明显降低。与TBI组相比，使用Harmine治疗后3和5天的逃逸潜伏期明显缩短。与未使用Harmine治疗的TBI组相比，TBI后使用Harmine明显改善大鼠TBI后1、3和5天的运动功能恢复。与TBI组相比，使用Harmine治疗组的神经元存活率明显提高。与TBI组相比，使用Harmine后GLT-1表达明显升高。与TBI组相比，使用Harmine明显降低caspase 3的表达^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

212.25

Formula

C₁₃H₁₂N₂O

CAS 号

442-51-3

性状

固体

颜色

White to yellow

中文名称

去氢骆驼蓬碱；肉叶芸香碱；哈尔明碱

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 30 mg/mL (141.34 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.7114 mL	23.5571 mL	47.1143 mL
5 mM	0.9423 mL	4.7114 mL	9.4229 mL
10 mM	0.4711 mL	2.3557 mL	4.7114 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.78 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (11.78 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.88%

选择批次：

Data Sheet (650 KB) SDS (394 KB)

COA (195 KB) LCMS (93 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Glennon RA, et al. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend. 2000 Aug 1;60(2):121-32. [Content Brief]

[2]. Neumann F, et al. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Sci Rep. 2018 Feb 12;8(1):2859. [Content Brief]

[3]. Zhang L, et al. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol Ther. 2015;16(11):1585-92. [Content Brief]

[4]. Zhong Z, et al. Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury. Mol Med Rep. 2015 Dec;12(6):7985-91. [Content Brief]

Animal Administration ^[4]	Rats^[4] A total of 150 male Sprague-Dawley rats (age, 10-12 weeks; weighing, 280-320 g; are used in the present study. The rats are randomly divided into three groups: Sham-operated group (sham; n=15); the TBI group (TBI; n=35) and the TBI + Harmine-treated group (Harmine; n=35). Harmine is administered immediately following TBI (i.p, 30 mg/kg per day) for up to 5 days. The sham and TBI groups receive equal volumes of 0.9% saline solution (i.p.). The rats are grouped as follows for examination of behavioral recovery: Sham, n=3; TBI, n=7; and Harmine, n=7. Following TBI, the NSS is evaluated at 1, 3 and 5 days. Each rat is assessed by an observer who is blinded to the animal treatment^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Glennon RA, et al. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend. 2000 Aug 1;60(2):121-32. [Content Brief] [2]. Neumann F, et al. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Sci Rep. 2018 Feb 12;8(1):2859. [Content Brief] [3]. Zhang L, et al. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol Ther. 2015;16(11):1585-92. [Content Brief] [4]. Zhong Z, et al. Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury. Mol Med Rep. 2015 Dec;12(6):7985-91. [Content Brief]

Animal Administration
^[4]

Rats^[4]
A total of 150 male Sprague-Dawley rats (age, 10-12 weeks; weighing, 280-320 g; are used in the present study. The rats are randomly divided into three groups: Sham-operated group (sham; n=15); the TBI group (TBI; n=35) and the TBI + Harmine-treated group (Harmine; n=35). Harmine is administered immediately following TBI (i.p, 30 mg/kg per day) for up to 5 days. The sham and TBI groups receive equal volumes of 0.9% saline solution (i.p.). The rats are grouped as follows for examination of behavioral recovery: Sham, n=3; TBI, n=7; and Harmine, n=7. Following TBI, the NSS is evaluated at 1, 3 and 5 days. Each rat is assessed by an observer who is blinded to the animal treatment^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Glennon RA, et al. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend. 2000 Aug 1;60(2):121-32. [Content Brief]

[2]. Neumann F, et al. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Sci Rep. 2018 Feb 12;8(1):2859. [Content Brief]

[3]. Zhang L, et al. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol Ther. 2015;16(11):1585-92. [Content Brief]

[4]. Zhong Z, et al. Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury. Mol Med Rep. 2015 Dec;12(6):7985-91. [Content Brief]

Harmine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.7114 mL	23.5571 mL	47.1143 mL	117.7856 mL
	5 mM	0.9423 mL	4.7114 mL	9.4229 mL	23.5571 mL
	10 mM	0.4711 mL	2.3557 mL	4.7114 mL	11.7786 mL
	15 mM	0.3141 mL	1.5705 mL	3.1410 mL	7.8524 mL
	20 mM	0.2356 mL	1.1779 mL	2.3557 mL	5.8893 mL
	25 mM	0.1885 mL	0.9423 mL	1.8846 mL	4.7114 mL
	30 mM	0.1570 mL	0.7852 mL	1.5705 mL	3.9262 mL
	40 mM	0.1178 mL	0.5889 mL	1.1779 mL	2.9446 mL
	50 mM	0.0942 mL	0.4711 mL	0.9423 mL	2.3557 mL
	60 mM	0.0785 mL	0.3926 mL	0.7852 mL	1.9631 mL
	80 mM	0.0589 mL	0.2945 mL	0.5889 mL	1.4723 mL
	100 mM	0.0471 mL	0.2356 mL	0.4711 mL	1.1779 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Harmine442-51-3Telepathine去氢骆驼蓬碱肉叶芸香碱哈尔明碱DYRK5-HT ReceptorDual specificity tyrosine phosphorylation regulated kinaseDual specificity tyrosine regulated kinaseSerotonin Receptor5-hydroxytryptamine ReceptorInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Harmine (Synonyms: 去氢骆驼蓬碱; Telepathine)

Customer Review

Other Forms of Harmine:

MCE 顾客使用本产品发表的 21 篇科研文献

Harmine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 DYRK 亚型特异性产品:

查看 5-HT Receptor 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Harmine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Harmine (Synonyms: 去氢骆驼蓬碱; Telepathine)

Customer Review

Other Forms of Harmine:

Harmine 相关抗体

MCE 顾客使用本产品发表的 21 篇科研文献

Harmine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 DYRK 亚型特异性产品:

查看 5-HT Receptor 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Harmine 相关抗体:

摩尔计算器

稀释计算器

Harmine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z